- Condition: Human Immunodeficiency Virus
Interventions: Drug: Atazanavir, ritonavir, lamivudine; Drug: Atazanavir, Ritonavir, 2 NRTIs
Sponsors: Catholic University of the Sacred Heart; Catholic University of the Sacred Heart
Recruiting - verified May 2012 - Condition: Locally Advanced Rectal Cancer
Interventions: Drug: veliparib; Drug: capecitabine; Radiation: radiation
Sponsors: Abbott; Abbott
Not yet recruiting - verified March 2012 - Condition: Diabetic Neuropathic Pain
Interventions: Drug: ABT-639; Drug: Placebo; Drug: Lidocaine
Sponsors: Abbott; Abbott
Not yet recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199; Drug: Bendamustine; Drug: Rituximab
Sponsors: Abbott; Abbott; Genentech
Not yet recruiting - verified May 2012 - Condition: Diabetic Neuropathic Pain
Interventions: Drug: ABT-652 6 mg; Drug: ABT-652 12 mg; Drug: ABT-652 12 mg - 18 mg; Drug: Placebo comparator; Drug: Duloxetine
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Stillborn Caesarean Section
Interventions: Drug: Bupivacaine plain; Drug: Ropivacaine plain; Drug: Levobupivacaine plain; Drug: bupivacaine plain +fentanyl; Drug: ropivacaine plain +. fentanyl; Drug: Levobupivacaine plain +fentanyl
Sponsors: University of Patras; University of Patras
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Device: Heart rate informed SSM+HMM
Sponsors: University of Virginia; University of Virginia; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom, Inc.; Insulet Corporation; Abbott Diabetes Care
Not yet recruiting - verified April 2012 - Conditions: Cardiovascular Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Coronary Restenosis; Heart Diseases; Coronary Stenosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases
Intervention:
Sponsors: Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.; Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.; Abbott Vascular
Recruiting - verified May 2012 - Conditions: Infant; Gastrointestinal Intolerance
Intervention: Other: Experimental Hydrolyzed infant formula
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified April 2012 - Condition: Coronary Artery Disease
Intervention: Device: CADence System
Sponsors: AUM Cardiovascular, Inc.; AUM Cardiovascular, Inc.
Not yet recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Adalimumab; Drug: Current adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Psoriatic Arthritis
Intervention:
Sponsors: Abbott; Abbott; CATO Research Canada; JSS Medical Research Inc.
Recruiting - verified March 2012 - Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Navitoclax
Sponsors: Abbott; Abbott
Not yet recruiting - verified March 2012 - Conditions: Hypertension; Stroke
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Post-anesthesia Recovery; Orientation
Interventions: Drug: Ketamine; Drug: Methohexital
Sponsors: University of New Mexico; University of New Mexico
Recruiting - verified March 2012 - Condition: Ulcerative Colitis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Not yet recruiting - verified March 2011 - Condition: Alzheimer's Disease
Interventions: Drug: ABT-126; Drug: ABT-126; Drug: placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Plaque Psoriasis; Crohn's Disease
Interventions: Drug: Adalimumab; Device: Capsule endoscopy
Sponsors: Innovaderm Research Inc.; Innovaderm Research Inc.; Abbott
Not yet recruiting - verified March 2012 - Condition: Carotid Artery Stenosis
Interventions: Device: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA); Device: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)
Sponsors: Fogarty Clinical Research Inc.; Fogarty Clinical Research Inc.; Abbott Vascular; Helen Kay Foundation; Northern Michigan Hospital Foundation's Louis A. and Sally Cannon
Recruiting - verified March 2012 - Conditions: Crohn's Disease; Mucosal Inflammation
Interventions: Drug: ADALIMUMAB; Drug: Placebo
Sponsors: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa; Abbott; INC Research
Not yet recruiting - verified March 2012 - Condition: Non-Small -Cell Lung Cancer
Interventions: Drug: Veliparib; Drug: Carboplatin; Drug: paclitaxel; Drug: placebo
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Stable Angina; Unstable Angina; NSTEMI
Interventions: Device: Amphilimus Eluting Stent; Device: Bare Metal Stent
Sponsors: CID - Carbostent & Implantable Devices; CID - Carbostent & Implantable Devices
Recruiting - verified February 2012 - Conditions: Hyperglycaemia; Hypoglycaemia
Intervention: Device: Freestyle Navigator
Sponsors: Onze Lieve Vrouwe Gasthuis; Onze Lieve Vrouwe Gasthuis
Recruiting - verified February 2012 - Condition: Irregular Menstrual Cycle
Intervention:
Sponsors: Abbott; Abbott
Not yet recruiting - verified January 2012 - Condition: HIV
Intervention: Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Sponsors: Fenway Community Health; Kenneth H. Mayer, MD; Bristol-Myers Squibb; Gilead Sciences; Abbott
Recruiting - verified May 2012 - Condition: HCV Infection
Interventions: Drug: ABT-267; Drug: ABT-450/r; Drug: ABT-333; Drug: Ribavirin (RBV)
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Heart Failure
Interventions: Other: Palliative Care Interventions; Other: Control
Sponsors: Abbott Northwestern Hospital; Abbott Northwestern Hospital; Allina Hospitals and Clinics
Recruiting - verified April 2012 - Condition: Subjects Who Were Previously Implanted With a Trifecta Valve.
Intervention:
Sponsors: St. Jude Medical; St. Jude Medical
Recruiting - verified January 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Device: FreeStyle InsuLinx; Device: FreeStyle Freedom Lite
Sponsors: Abbott Diabetes Care; Abbott Diabetes Care
Recruiting - verified April 2012 - Conditions: Stage 5 Chronic Kidney Diseases; Moderate to Severe Secondary Hyperparathyroidism
Intervention: Drug: Paricalcitol
Sponsors: Abbott; Abbott
Not yet recruiting - verified April 2012 - Condition: Schizophrenia
Intervention: Drug: SLV354
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Respiratory Syncytial Virus Infection
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Ulcerative Colitis
Intervention: Drug: Adalimumab
Sponsors: Clalit Health Services; Clalit Health Services
Not yet recruiting - verified December 2011 - Condition: Arthritis; Behcet
Intervention: Drug: Adalimumab (Humira)
Sponsors: Rambam Health Care Campus; Rambam Health Care Campus; Abbott
Not yet recruiting - verified December 2011 - Condition: Coronary Artery Disease
Interventions: Device: platinum chromium everolimus-eluting stent; Device: cobalt chromium everolimus-eluting stent
Sponsors: University of Roma La Sapienza; University of Roma La Sapienza
Not yet recruiting - verified December 2011 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Veliparib and 5-FU and Oxaliplatin and Leucovorin
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified December 2011 - Condition: Coronary Artery Disease
Intervention: Device: percutaneous coronary intervention ((RESOLUTE INTEGRITY stent) (XIENCE PRIME stent)
Sponsors: CardioVascular Research Foundation, Korea; Duk-Woo Park; Abbott
Recruiting - verified April 2012 - Condition: Critical Limb Ischemia
Interventions: Biological: Ixmyelocel-T; Other: Vehicle Control
Sponsors: Aastrom Biosciences; Aastrom Biosciences
Recruiting - verified May 2012 - Condition: Elderly
Interventions: Other: Oral medical nutritional supplement; Other: Experimental oral medical nutritional supplement with AN777
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified November 2011 - Condition: Pneumonia
Interventions: Other: Experimental Oral Nutritional Supplement; Dietary Supplement: No Product
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified November 2011 - Conditions: Coronary Artery Disease; Coronary Disease; Coronary Stenosis
Intervention: Device: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Sponsors: R&D Cardiologie; R&D Cardiologie; Biotronik SE & Co. KG
Recruiting - verified March 2012 - Conditions: Ankylosing Spondylitis; Psoriatic Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Optimus Clinical Research; Optimus Clinical Research; Arthritis Australia, Abbott Australia
Recruiting - verified November 2011 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Hidradenitis Suppurativa (HS)
Interventions: Biological: adalimumab; Biological: placebo; Biological: adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Intervention: Drug: ABT-888/Bortezomib
Sponsors: Alberta Health Services; Alberta Health Services; Tom Baker Cancer Centre; Abbott
Recruiting - verified December 2011 - Conditions: Atherosclerosis; Peripheral Vascular Disease; Claudication
Intervention: Device: ESPRIT BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified May 2012 - Condition: Crohn's Disease
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Type 2 Diabetics; Chronic Kidney Disease; Protein in Urine
Interventions: Drug: ABT-614; Drug: Placebo Comparator
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Arthritis; Rheumatoid
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Restenosis
Intervention:
Sponsors: Gilard, Martine; Gilard, Martine; Clinical Research Organization and study management; Abbott Vascular
Not yet recruiting - verified November 2011 - Conditions: Dyslipidemias; Hypertriglyceridemia; Cardiovascular Diseases
Intervention: Drug: fenofibrate
Sponsors: Abbott; Abbott; RUNDO International Pharmaceuticals Research & Development Co., Ltd
Recruiting - verified April 2012 - Condition: Lymphoma
Interventions: Drug: alisertib; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
Sponsors: Vejle Hospital; Vejle Hospital; Abbott
Recruiting - verified December 2011 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-806; Drug: ABT-806i
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Stress Induced GI Bleeding; C. Difficile Colitis
Interventions: Drug: Pantoprazole 40 mg IV daily will be given with tube feed.; Other: Placebo and tube feed
Sponsors: University of Louisville; Mohamed Saad; Abbott Nutrition; University of Louisville; Jewish Hospital and St. Mary's Healthcare
Recruiting - verified November 2011 - Conditions: Carotid Artery Disease; Stroke; Amaurosis Fugax; Transient Ischemic Attack (TIA)
Intervention: Device: RX Acculink Carotid Stent System (RX Acculink)
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified May 2012 - Condition: Advanced Parkinson's Disease
Intervention: Drug: ABT-SLV187
Sponsors: Abbott; Abbott; Abbott Japan Co.,Ltd
Recruiting - verified February 2012 - Condition: Peripheral Arterial Disease
Intervention: Device: stent
Sponsors: Flanders Medical Research Program; Flanders Medical Research Program
Recruiting - verified September 2011 - Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r; Drug: ABT-267; Drug: ribavirin
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Critical Illness; Enteral Feeding
Interventions: Other: VITAL AF; Other: Osmolite 1.2
Sponsors: Columbia University; Columbia University; Abbott Nutrition
Recruiting - verified November 2011 - Condition: Pain
Interventions: Drug: 150% Oral Morphine Equivalent (OME); Other: Clinical Judgment
Sponsors: Abbott Northwestern Hospital; Abbott Northwestern Hospital; Allina Hospitals and Clinics
Recruiting - verified October 2011 - Conditions: Peripheral Artery Disease; Peripheral Vascular Disease
Intervention: Device: Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012 - Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Conditions: Coronary Artery Disease (CAD); Chronic Total Occlusion (CTO)
Intervention: Device: CTO Treatment Device
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012 - Conditions: Uterine Fibroids; Heavy Uterine Bleeding
Interventions: Drug: placebo; Drug: elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo Cohort 4; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified April 2012 - Conditions: Coronary Artery Disease; Angina Pectoris
Interventions: Drug: Ranolazine; Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified April 2012 - Conditions: Disorder of Transplanted Kidney; Proteinuria; Albuminuria
Interventions: Drug: Paricalcitol; Drug: Placebo
Sponsors: University Medical Centre Ljubljana; University Medical Centre Ljubljana; Abbott
Not yet recruiting - verified September 2011 - Conditions: Severe Crohn's Disease; Anxiety
Intervention:
Sponsors: Abbott; Abbott; Raffeiner GmbH
Recruiting - verified December 2011 - Conditions: Cystic Fibrosis; Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Exocrine Pancreatic Insufficiency; Pancreatic Diseases; Digestive System Diseases
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Coronary Artery Disease
Interventions: Device: Abbott Vascular XIENCE PRIME Everolimus Eluting Coronary Stent System; Device: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012 - Conditions: Malnourished; Stomach Neoplasms; Gastrointestinal Stromal Tumors
Interventions: Dietary Supplement: Ensure powder; Other: Standard care
Sponsors: Seoul National University Hospital; Seoul National University Hospital; Abbott
Recruiting - verified August 2011 - Conditions: Atherosclerosis; Coronary Artery Disease
Intervention: Device: OMEGA™ Monorail Coronary Stent System (CSS)
Sponsors: Boston Scientific Corporation; Boston Scientific Corporation
Recruiting - verified May 2012 - Condition: Uncontrolled Hypertension
Intervention: Device: Renal denervation (Symplicity Catheter System)
Sponsors: Medtronic Vascular; Medtronic Vascular
Recruiting - verified May 2012 - Condition: Arthritis, Juvenile Rheumatoid
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Toowoomba Regional Cancer Research Centre; Toowoomba Regional Cancer Research Centre; Abbott
Recruiting - verified June 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: ABT-806
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott; Almedis
Recruiting - verified January 2012 - Conditions: Diabetic Nephropathy; Chronic Kidney Disease
Interventions: Drug: Atrasentan; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Myocardial Infarction; Multivessel Coronary Disease
Interventions: Procedure: FFR-guided revascularisation strategy; Procedure: staged revascularisation
Sponsors: Maasstad Hospital; Maasstad Hospital; Abbott Vascular; St. Jude Medical
Recruiting - verified September 2011 - Condition: Coronary Artery Disease
Interventions: Device: Bio-degradable polymer stent; Device: Durable polymer stent
Sponsors: Yonsei University; Yonsei University
Not yet recruiting - verified July 2011 - Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Daclizumab High Yield Process prefilled syringe
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Paricalcitol; Other: placebo
Sponsors: Mario Negri Institute for Pharmacological Research; Mario Negri Institute for Pharmacological Research; Abbott
Not yet recruiting - verified July 2011 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Psoriasis
Intervention:
Sponsors: Abbott; Abbott; CATO Research Canada; JSS Medical Research Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CATO Research Canada
Recruiting - verified April 2012 - Conditions: Moderate to Severe Plaque Psoriasis; Antibodies; Monoclonals
Intervention:
Sponsors: Abbott; Abbott; Mag. Andreas Raffeiner GMBH
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CMX Research; CMX Research Inc
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Secondary Hyperparathyroidism; End-Stage Renal Disease
Intervention: Drug: Paricalcitol
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: linifanib
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab
Sponsors: The Rheumatological Center of Helsinki; The Rheumatological Center of Helsinki; Abbott
Recruiting - verified July 2011 - Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Preterm Infants
Interventions: Other: Experimental human milk fortifier; Other: Control human milk fortifier
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified December 2011 - Condition: Brain Injury
Intervention: Drug: 1: Sevoflurane
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Ministry of Health, France
Recruiting - verified April 2012 - Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Folliculogenesis
Interventions: Drug: Elagolix; Drug: Elagolix; Drug: Elagolix; Drug: Elagolix; Drug: Elagolix Dose Regimen 5; Drug: Elagolix Dose Regimen 6; Drug: elagolix dose regimen 7
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified February 2012 - Condition: Congestive Heart Failure
Interventions: Device: HeartWare® VAS; Other: Optimal Medical Management
Sponsors: University of Michigan; University of Michigan; HeartWare, Inc.; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: Observational study
Sponsors: Canadian Research & Education in Arthritis; Canadian Research & Education in Arthritis; Abbott
Recruiting - verified November 2011 - Conditions: Uveitis; Juvenile Arthritis
Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody; Drug: placebo
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Abbott
Recruiting - verified July 2011 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Heart Failure; Hypogonadism
Intervention: Drug: testerone gel
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center; Abbott
Not yet recruiting - verified April 2011 - Condition: Corneal Astigmatism
Intervention: Device: iFS Femtosecond Laser System
Sponsors: Abbott Medical Optics; Abbott Medical Optics
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Psoriasis; Atherosclerosis
Intervention: Drug: biological treatment
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Aage Bangs Fond; Abbott; Region Midt Forskningsfond
Recruiting - verified May 2012 - Conditions: Atherosclerosis; Peripheral Artery Disease; Peripheral Vascular Disease; PAD; Claudication; Critical Limb Ischemia; Lower Limb Disease; Peripheral Arterial Occlusive Disease; PAOD; PVD
Intervention: Device: Everolimus Eluting BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012 - Condition: Crohn's Disease
Intervention: Drug: Adalimumab and Infliximab
Sponsors: University Hospital, Ghent; University Hospital, Ghent; Abbott
Recruiting - verified November 2011 - Conditions: Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian; Fallopian Tube; or Primary Peritoneal Cancer
Intervention: Drug: ABT-767
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infectionCondition: Human Immunodeficiency Virus Infection
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma
Intervention: Drug: ABT-199
Sponsors: Abbott; Abbott; Genentech
Recruiting - verified March 2012 - Condition: Psoriasis
Intervention:
Sponsors: Abbott; Abbott; pH Associates
Recruiting - verified February 2012 - Condition: Ankylosing Spondylitis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vitamin D Deficiency
Interventions: Dietary Supplement: Vitamin D and Calcium Citrate; Dietary Supplement: Placebo
Sponsors: Children's Hospital Los Angeles; Children's Hospital Los Angeles; The Leukemia and Lymphoma Society
Recruiting - verified September 2011 - Condition: HIV-1 Infection
Interventions: Procedure: cervical cryotherapy; Procedure: Loop Electrosurgical Excision Procedure (LEEP)
Sponsors: AIDS Clinical Trials Group; AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified February 2012 - Conditions: Type 1 Diabetes Mellitus; Retinopathy; Diabetic Nephropathy
Interventions: Drug: Fenofibrate; Drug: Inert lactose placebo
Sponsors: University of Sydney; University of Sydney; Abbott; University of Melbourne; St Vincents Hospital, Melbourne; Melbourne Health; Royal Prince Alfred Hospital, Sydney, Australia
Not yet recruiting - verified March 2011 - Condition: Psoriasis
Intervention: Drug: Adalimumab
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Abbott
Recruiting - verified September 2011 - Condition: Coronary Artery Disease
Interventions: Device: Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS); Device: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified April 2012 - Condition: Heart Diseases
Interventions: Dietary Supplement: Ensure, Abbott Nutrition; Other: standard hospital diet
Sponsors: Meshalkin Research Institute of Pathology of Circulation; Meshalkin Research Institute of Pathology of Circulation
Recruiting - verified April 2012 - Condition: Infant Newborn
Interventions: Other: Human Milk; Other: Investigational infant formula; Other: Milk based standard infant formula
Sponsors: Abbott Nutrition; Abbott Nutrition; Institute of Child Health
Recruiting - verified November 2011 - Condition: Respiratory Syncytial Virus Infection
Intervention:
Sponsors: Abbott; Abbott; Fundasamin (Argentina)
Recruiting - verified March 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; Almedis
Recruiting - verified February 2012 - Conditions: Psoriasis; Psoriatic Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Osteoarthritis
Interventions: Other: Exercise; Other: manual therapy
Sponsors: Agency for Healthcare Research and Quality (AHRQ); Agency for Healthcare Research and Quality (AHRQ)
Recruiting - verified November 2010 - Condition: Coronary Artery Disease
Intervention:
Sponsors: University of Pittsburgh; University of Pittsburgh; Abbott
Recruiting - verified January 2012 - Conditions: Acute Decompensated Heart Failure; Acute Kidney Injury
Intervention:
Sponsors: Abbott Diagnostics Division; Abbott Diagnostics Division; Alere, Inc.
Recruiting - verified February 2012 - Conditions: Chlamydia Infection; Gonococcal Infection; Sexually Transmitted Diseases
Intervention:
Sponsors: University of California, San Francisco; University of California, San Francisco; Abbott Molecular
Not yet recruiting - verified April 2012 - Condition: Interstitial Cystitis
Interventions: Drug: Adalimumab; Other: inactive drug
Sponsors: ICStudy, LLC; ICStudy, LLC; Abbott
Recruiting - verified May 2012 - Conditions: Coronary Artery Disease; Diabetes Mellitus
Interventions: Device: Taxus Element stent; Device: Integrity Resolute stent; Device: Xience Prime stent
Sponsors: Policlinico Casilino ASL RMB; Policlinico Casilino ASL RMB; Azienda Ospedaliera - Universitaria di Modena
Recruiting - verified August 2011 - Condition: Contrast Media Induced Nephropathy (CIN)
Interventions: Other: application of intravenous volume; Other: oral fluid application
Sponsors: Medical University of Graz; Medical University of Graz; Abbott Diagnostics Division
Recruiting - verified October 2011 - Condition: Crohn's Disease
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: HIV Infection
Intervention: Drug: Lopinavir/ritonavir (LPV/r)
Sponsors: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; International Maternal Pediatric Adolescent AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Abbott
Recruiting - verified May 2012 - Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012 - Condition: Oral Mucositis
Interventions: Device: MuGard; Device: Control Rinse
Sponsors: Access Pharmaceuticals, Inc.; Access Pharmaceuticals, Inc.
Recruiting - verified April 2012 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCondition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Coronary Artery Disease; Aortic Aneurysm; Pulmonary Embolism
Intervention:
Sponsors: William Beaumont Hospitals; William Beaumont Hospitals; Siemens Healthcare Diagnostics Inc
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Plaque Psoriasis
Interventions: Biological: Adalimumab - Low Dose; Biological: Adalimumab - Standard Dose; Drug: Methotrexate; Biological: Adalimumab - Open-Label
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease
Intervention:
Sponsors: Abbott; Abbott; Pharma Consulting Group
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: bicalutamide; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: ABT-806
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: In-stent Restenosis
Interventions: Device: Coronary angioplasty using the paclitaxel-eluting balloon; Device: Coronary angioplasty using the Everolimus-eluting stent
Sponsors: Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular; Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular; Hospital Clinico San Carlos, Madrid; B.Braun Surgical SA; Abbott Vascular
Recruiting - verified November 2010 - Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Crohn's Disease
Interventions: Biological: adalimumab; Drug: prednisone; Drug: azathioprine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: HIV Infections
Interventions: Drug: lopinavir/ritonavir plus one nucleoside; Drug: lopinavir /ritonavir plus two nucleosides
Sponsors: The Huesped Foundation; The Huesped Foundation; Abbott
Recruiting - verified November 2010 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bendamustine hydrochloride; Drug: bortezomib; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)Conditions: Chronic Kidney Disease; Secondary Hyperparathyroidism
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Chronic Coronary Occlusion; Unprotected Left Main Coronary Artery Disease; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis
Interventions: Device: Percutaneous Coronary Intervention; Procedure: CABG
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified April 2012 - Conditions: Chronic Coronary Occlusion; Left Main Coronary Artery Disease; Stent Thrombosis; Vascular Disease; Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis
Intervention:
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified April 2012 - Condition: Moderate to Severe Plaque Psoriasis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified November 2011 - Condition: Cardiovascular Diseases
Intervention:
Sponsors: Abbott; Abbott; QUASY
Recruiting - verified April 2012 - Condition: Hepatocellular Carcinoma
Intervention: Drug: temozolomide + ABT-888
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified October 2011 - Condition: Rheumatoid Arthritis
Intervention: Device: Ultrasonography
Sponsors: Diakonhjemmet Hospital; Espen A. Haavardsholm; The Research Council of Norway; Smerud Medical Research International AS; Oslo University Hospital, Section for GCP; Innovest; Abbott; UCB NORDIC A/S; Pfizer; MSD Norway AS; Roche Pharma AG; The Norwegian Rheumatism Association
Recruiting - verified April 2012 - Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Malnutrition; Sarcopenia
Interventions: Other: medical food with AN777; Other: oral nutritional formula
Sponsors: Abbott Nutrition; Abbott Nutrition
Recruiting - verified November 2011 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Conditions: Arthritis, Rheumatoid; Pain; Fatigue
Interventions: Drug: adalimumab; Drug: Placebo
Sponsors: Karolinska Institutet; Karolinska Institutet; Abbott; Swedish Foundation for Strategic Research; The Swedish Research Council
Recruiting - verified August 2011 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Biological: Humira (adalimumab); Drug: Methotrexate (MTX)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Conditions: Atrial Fibrillation; Stroke
Interventions: Device: WATCHMAN Device; Drug: Warfarin
Sponsors: Atritech; Atritech
Recruiting - verified April 2012 - Condition: HIV-1
Interventions: Drug: Efavirenz or Nevirapine; Drug: Ritonavir-boosted lopinavir
Sponsors: University of Aarhus; University of Aarhus; Aarhus University Hospital; Bandim Health Project; Ministry of Health, Guinea-Bissau; Abbott
Recruiting - verified November 2011 - Condition: Psoriasis
Intervention:
Sponsors: Abbott; Abbott; Veeda Clinical Research, Brussels
Recruiting - verified May 2012 - Conditions: Spondyloarthritis; Intestinal Inflammation
Intervention: Drug: Adalimumab
Sponsors: Regionshospitalet Silkeborg; Regionshospitalet Silkeborg; Abbott; European Capsule Endoscopy Group; The Central Denmark Region
Recruiting - verified July 2011 - Condition: Moderate to Severe Psoriasis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Psoriasis
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Obesity
Interventions: Drug: Leuprolide; Drug: Testosterone
Sponsors: Mayo Clinic; Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Abbott
Recruiting - verified January 2012 - Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Secondary Hyperparathyroidism; End Stage Renal Disease
Intervention:
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Secondary Hyperparathyroidism; End-Stage Renal Disease
Interventions: Drug: Paricalcitol; Drug: Calcitriol
Sponsors: Abbott; Abbott; North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
Recruiting - verified January 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Arthritis, Rheumatoid
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott; Mount Sinai Hospital, Canada
Recruiting - verified December 2011 - Conditions: Gastric Bypass; Parathyroid Hormone
Interventions: Drug: Paricalcitol; Drug: Cholecalciferol; Drug: Placebo
Sponsors: William Beaumont Hospitals; William Beaumont Hospitals; Abbott
Recruiting - verified September 2011 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Condition: Epithelial Ovarian Cancer
Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform; Procedure: HE4 assay on Architect i1000SR platform; Procedure: Transvaginal Ultrasound
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; The Marsha Rivkin Center for Ovarian Cancer Research; Canary Foundation; Swedish Medical Center; Beckman Research Institute; Cedars-Sinai Medical Center; Stanford University; Fox Chase Cancer Center
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott; University Health Network, Toronto
Recruiting - verified May 2012 - Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Colorectal Cancer
Intervention: Drug: Veliparib
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Crohn's Disease
Intervention:
Sponsors: University of Calgary; University of Calgary; Abbott
Recruiting - verified January 2011 - Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: ABT-348; Drug: ABT-348 and carboplatin; Drug: ABT-348 and docetaxel; Drug: ABT-348; Drug: ABT-348
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Fecal Incontinence
Intervention: Device: TOPAS Sling System
Sponsors: American Medical Systems; American Medical Systems
Recruiting - verified May 2012 - Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: palivizumab (Synagis)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis
Intervention: Biological: HUMIRA (adalimumab)
Sponsors: Abbott; Abbott; Veeda Clinical Research, Brussels
Recruiting - verified March 2012 - Condition: Ankylosing Spondylitis
Intervention: Drug: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Conditions: Crohn's Disease; Rheumatoid Arthritis
Intervention:
Sponsors: University of California, San Diego; University of California, San Diego; The Organization of Teratology Information Specialists; Abbott
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: This is a non-drug study. No treatment is mandated by the protocol. Routine blood draws (as per normal clinical care) will be taken through the study.
Sponsors: Abbott; Abbott; Clinical Trial End-Point (CTEP) Ltd; JSS Medical Research Inc.
Recruiting - verified February 2012 - Condition: Psoriatic Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Psoriatic Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Not yet recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Crohn´s Disease
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical PracticeCondition: Rheumatoid Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified December 2011 - Condition: Moderate to Severe Plaque Psoriasis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified February 2012 - Conditions: Active Rheumatoid Arthritis; Osteoporoses
Intervention:
Sponsors: Abbott; Abbott; Centre of Biostatistics and Analyses, Faculty of Medicine, Masaryk University Brno, Czech Republic
Recruiting - verified February 2012 - Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
Sponsors: Abbott; Abbott; Veeda Clinical Research, Belgium
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: adalimumab (Humira)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Conditions: Kidney Insufficiency; Secondary Hyperparathyroidism
Intervention: Drug: Zemplar (paricalcitol)
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Human Immunodeficiency Virus
Interventions: Drug: lopinavir/ritonavir; Drug: Raltegravir
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Chronic Plaque Psoriasis
Intervention: Biological: adalimumab (HUMIRA)
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Respiratory Tract Infection
Intervention: Drug: clarithromycin (Klacid XL)
Sponsors: Abbott; Abbott; Eilaf CRO
Recruiting - verified February 2012 - Condition: Crohn's Disease
Intervention:
Sponsors: Haukeland University Hospital; Haukeland University Hospital; University of Bergen; Abbott
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Interventions: Drug: veliparib (ABT-888); Drug: carboplatin; Drug: gemcitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012 - Conditions: Alcohol Dependence; PTSD
Interventions: Drug: Propranolol; Drug: Placebo
Sponsors: Medical University of South Carolina; Medical University of South Carolina; National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified November 2011 - Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified July 2011 - Condition: Colorectal Cancer
Intervention: Drug: Temozolomide and ABT-888
Sponsors: Georgetown University; Georgetown University; Abbott
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Myocardial Ischemia; Coronary Artery Stenosis; Coronary Disease; Coronary Artery Disease; Coronary Restenosis; Cardiovascular Disease
Intervention: Device: ABSORB BVS
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified March 2012 - Condition: Chronic Kidney Disease Stage 3 and 4
Interventions: Drug: Zemplar (paricalcitol) Capsules; Drug: Placebo capsules
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Myocardial Ischemia
Intervention: Genetic: VM202
Sponsors: ViroMed Co., Ltd.; ViroMed Co., Ltd.; VM Biopharma
Not yet recruiting - verified February 2012 - Condition: Cerebral Aneurysms
Intervention:
Sponsors: Mayo Clinic; David F. Kallmes; Baylor University; Stony Brook University; Thomas Jefferson University; University of Maryland; University of Saskatchewan; University of Florida; Albany Medical College; Abbott
Recruiting - verified April 2012 - Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: panitumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Atherosclerosis
Intervention:
Sponsors: Piedmont Healthcare; Piedmont Healthcare; Abbott
Recruiting - verified October 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: HIV Infections
Interventions: Drug: Isentress®; Drug: Celsentri®
Sponsors: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer; Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer; Merck; Abbott
Recruiting - verified July 2009 - Condition: Psoriasis
Interventions: Drug: Methotrexate; Drug: Adalimumab (Humira)
Sponsors: Tufts Medical Center; Tufts Medical Center; Abbott
Recruiting - verified July 2011 - Condition: Contrast Induced Kidney Injury.
Intervention: Drug: sodium bicarbonate
Sponsors: MD Scientific; MD Scientific
Recruiting - verified February 2012 - Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Endothelial Dysfunction; Inflammatory Disease Activity
Intervention:
Sponsors: Revmatismesykehuset AS; Revmatismesykehuset AS; Abbott
Recruiting - verified May 2009 - Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Intervention: Drug: Nebivolol
Sponsors: Minneapolis Heart Institute Foundation; Minneapolis Heart Institute Foundation; Forest Laboratories
Recruiting - verified June 2011 - Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Retinopathy of Prematurity
Intervention: Dietary Supplement: carotenoids
Sponsors: University of Utah; University of Utah; Abbott
Recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Implantable Cardioverter-Defibrillators
Intervention:
Sponsors: Minneapolis Heart Institute Foundation; Minneapolis Heart Institute Foundation
Recruiting - verified June 2011 - Condition: Chronic Plaque Psoriasis
Intervention: Biological: HUMIRA® (adalimumab)
Sponsors: Abbott; Abbott
Recruiting - verified January 2012 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Andropause
Intervention: Drug: AndroGel® (testosterone gel)
Sponsors: University of Pennsylvania; University of Pennsylvania; National Institute on Aging (NIA); National Institute of Neurological Disorders and Stroke (NINDS); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Heart, Lung, and Blood Institute (NHLBI); Abbott
Recruiting - verified January 2012 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Chronic Kidney Disease; Vitamin D Deficiency; Coronary Calcification; Disorders of Calcium and Bone Metabolism
Interventions: Drug: Calcitriol (Rocaltrol®); Drug: Paricalcitol
Sponsors: University of Pennsylvania; University of Pennsylvania; Abbott
Recruiting - verified November 2011 - Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Renal Artery Stenosis
Interventions: Device: Herkulink renal artery Stent; Other: best medical therapy
Sponsors: Medical University of Vienna; Medical University of Vienna
Recruiting - verified July 2011 - Conditions: Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Neoplasm Metastasis; Brain Neoplasms
Interventions: Drug: ABT-888; Radiation: Whole Brain Radiation Therapy
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Atrial Fibrillation
Interventions: Device: Epicor LP Cardiac Ablation System; Procedure: Surgical ablation of permanent AF
Sponsors: St. Jude Medical; St. Jude Medical
Recruiting - verified October 2011 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011 - Condition: Coronary Artery Disease
Interventions: Drug: AndroGel 5 Grams; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; Abbott
Recruiting - verified January 2012 - Condition: Carotid Artery Disease
Intervention: Device: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified January 2012 - Conditions: Migraine Headaches; Patent Foramen Ovale
Interventions: Other: Sham Procedure; Device: AMPLATZER PFO Occluder
Sponsors: AGA Medical Corporation; AGA Medical Corporation
Recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Anal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gemcitabine hydrochloride; Drug: paricalcitol
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; Abbott
Recruiting - verified January 2012 - Conditions: Carotid Artery Disease; Carotid Stenosis; Stroke; Atherosclerosis
Interventions: Device: Carotid artery stenting with filter (interventional); Procedure: Carotid artery endarterectomy (surgical)
Sponsors: Abbott Vascular; Abbott Vascular
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
 |
Join Clinical Trials in Hot Springs, Arkansas |
